11 July 2016

Excellency,

Please find enclosed for your kind attention a letter, dated 8 July, 2016, from the Facilitator on the modalities resolution for the High Level meeting on Antimicrobial Resistance, H.E. Mr. Juan Jose Gómez Camacho, Permanent Representative of Mexico, under cover of which he has forwarded the attached final draft resolution which is now under silent procedure until 6:00 p.m. on Wednesday, 13 July, 2016.

Please accept, Excellency, the assurances of my highest consideration.

Mogens Lykketoft

To all Permanent Representatives
And Permanent Observers to the United Nations
New York
New York, 8 July 2016.

Excellency,

I have the honor to refer to your letter dated 7 April 2016, appointing me as facilitator to lead open, transparent, and inclusive consultations with Member States to finalize the organizational arrangements, including a possible outcome for the *High-Level Meeting on Antimicrobial Resistance* of the plenary of the General Assembly, to be held on 21 September 2016.

In this regard, I wish to inform you that the attached resolution on the scope, modalities, format, and organization for the aforementioned High Level Meeting, has been finalized under informal informal consultations with Member States, and would appreciate very much your kind instructions so that it is put under silence procedure until Wednesday 13 of July 2016, 6:00 pm.

I am very glad to inform you that a very constructive engagement has prevailed in our consultations and that now they are being focused on the drafting of a robust outcome of this relevant High Level Meeting.

I avail myself of this opportunity to renew to your Excellency the assurances of my highest consideration.

Juan José Gómez Camacho
Ambassador
Permanent Representative of Mexico
to the United Nations

H.E. Mr. Mogens Lykketoft
President of the 70th Session
of the General Assembly
United Nations

Two United Nations Plaza, 28th Floor, New York, NY, 10017
Tel: (212) 752.0220 Fax: (212) 752.0634 http://mision.sre.gob.mx/ou/
Revised text of modalities resolution  
High-level meeting on antimicrobial resistance  

The General Assembly,  

Recalling its resolution 70/183 of 17 December 2015 on global health and foreign policy, in which it decided to hold a high-level meeting in 2016 on antimicrobial resistance and requested the Secretary-General, in collaboration with the Director General of the World Health Organization, and in consultation with Member States, as appropriate, to determine options and modalities for the conduct of such a meeting, including potential deliverables,  

Mindful of the need to summon and maintain strong national, regional and international political commitment in addressing antimicrobial resistance comprehensively and multi-sectorally, and to increase and improve awareness of antimicrobial resistance;  

Taking note of the report of the Secretary-General of 18 March 2016 on scope, modalities, format and organization of the high-level meeting on antimicrobial resistance convened by the President of the General Assembly,  

Emphasizing the important role and the responsibilities of governments, as well as the role of relevant inter-governmental organizations, particularly the World Health Organization within its mandate and in coordination with FAO and OIE, as appropriate, in responding to the challenges of antimicrobial resistance, and the essential need for multi-sectorial and cross-sectorial efforts and engagement of all relevant sectors of society, such as human and veterinary medicine, agriculture, finance, environment and consumers, to generate an effective response, including towards a one-health approach,  

Further recalling the World Health Assembly Resolution WHA 68.7 entitled “Global Action Plan on antimicrobial resistance” which reflects a global consensus that antimicrobial resistance poses a significant public health challenge, and emphasizing the paramount significance of achieving the five strategic objectives of the WHA Global Action Plan,  

1. **Decides** that the high-level meeting convened by the President of the General Assembly on antimicrobial resistance shall be held on 21 September 2016, from 10 a.m. to 1 p.m. and from 3 p.m. to 6 p.m., in New York;  

2. **Encourages all** Member States to participate in the High Level Meeting at the highest possible level, preferably at the level of Heads of State and Government;  

3. **Decides** that the organizational arrangements of the high-level meeting shall be as follows:  

---  

1 A/70/790
(a) An opening segment, which will include statements by the President of the General Assembly, the Secretary-General; the Director-General of the World Health Organization, the Director-General of the Food and Agriculture Organization and the Director-General of the World Organization for Animal Health, each speaking from their perspective and in accordance with the mission and mandate that each institution represents;

(b) Two interactive hour long thematic panels, each composed of up to six discussants, with three Heads of State and Government and three relevant stakeholders each, bearing in mind an equitable gender, level of development and geographical representation, on the following themes:

Panel 1: The relevance of addressing AMR for the achievement of the SDG's, in particular the health related SDGs,
Panel 2: Addressing the multisectoral implications and implementation challenges of AMR in a comprehensive manner,

(c) Panels 1 and 2 will take place during the morning session, in parallel to the plenary segment;

(d) The Plenary segment for general discussions during the morning and afternoon, will have three minute interventions by Member states. A list of speakers will be established in accordance with the rules of procedure and practices of the General Assembly;

(e) Closing segment by the President of the General Assembly with summaries of the thematic panel discussions and concluding remarks;

4. **Requests** the President of the General Assembly, with the support of the WHO, FAO and OIE to finalize the organizational arrangements for the thematic panels, taking into account the views of Member states and equitable gender, level of development and geographical representation, for the participation of Heads of State and Government, as well as of relevant civil society, private sector, academia and other stakeholders with expertise in AMR;

5. **Further requests** the facilitator of the consultations to lead an informal interactive dialogue with relevant AMR civil society as well as with relevant AMR private sector, as part of the preparatory process for the HLM;

6. **Invites** all relevant United Nation System entities, including programmes, funds, specialized agencies and regional commissions, as well as regional and subregional organizations, to participate in the High Level Meeting, contributing as appropriate, and to consider initiatives in support of its preparatory process;

7. **Invites** intergovernmental organizations and related entities that have observer status with the General Assembly, to be represented at the highest possible level;

8. **Also invites** non-governmental organizations that are in consultative status with the ECOSOC with relevant expertise to register with the Secretariat to attend the meeting;

9. **Encourages** Member States to consider, as appropriate, including in their national delegations parliamentarians, civil society, private sector, academia and other stakeholders working on antimicrobial resistance;
10. Requests the President of the General Assembly to draw up a list of other relevant representatives of relevant AMR non-governmental organizations, civil society organizations, academic institutions and the private sector who may attend the high-level meeting and participate in the interactive panel discussions, taking into account the principles of transparency and of equitable geographic representation, and with due regard to the meaningful participation of women, and to submit the list to Member States for their consideration on a non-objection basis*;

11. Decides that the high-level meeting shall approve a concise and action oriented declaration, agreed by consensus through intergovernmental consultations, to be submitted by the President of the General Assembly for adoption by the General Assembly.

* The list of proposed as well as final names will be brought to the attention of the General Assembly. Where a name is objected to, the objecting Member State will, on a voluntary basis, make known to the Office of the President of the General Assembly the general basis of its objections and the Office of the President of the General Assembly will share any information received with any Member State upon its request.